Astera Labs (ALAB) Stock Drops 14% After Insiders Cash Out Millions

TLDR

• ALAB fell as much as 14% on Monday, trading down to around $353, after closing Friday at $412.97
• Insider selling was a key driver, with Board Chairman Manuel Alba and Director Stefan Dyckerhoff liquidating millions in stock
• Global risk-off sentiment hit chip stocks after U.S. strikes on Iran and weakness in South Korean semiconductor names
• The stock remains up 113% year to date despite Monday’s drop
• Wall Street holds a consensus “Moderate Buy” rating with an average price target of $265.75

---

Astera Labs (ALAB) dropped sharply on Monday, falling as much as 14% intraday to around $353, after closing Friday at $412.97. Volume was a fraction of normal, with only around 547,000 shares changing hands versus an average of over 5.6 million.

Astera Labs, Inc. Common Stock, ALAB

The sell-off came from several directions at once. Insider liquidations, a risk-off macro environment, and index rebalancing all hit the stock on the same day.

SEC filings showed Board Chairman Manuel Alba sold 173,366 shares across multiple tranches, at prices ranging from $442 to $458. Director Stefan Dyckerhoff sold an additional 12,500 shares at $450. Both sales were executed under pre-arranged Rule 10b5-1 trading plans.

Over the last quarter, insiders have sold a combined $507 million worth of stock, a number that has caught the market’s attention.

Global Pressures Hit Chip Stocks

The broader semiconductor sector came under pressure after declines in South Korea’s Samsung and SK Hynix weighed on the KOSPI and spilled over into U.S. chip names.

Markets also turned cautious after the U.S. launched fresh strikes against Iran on Sunday evening. Crude oil climbed on the news, and the U.S. Central Command reported that Iran no longer controlled the Strait of Hormuz, raising supply chain concerns.

The Nasdaq fell 1.74% and the S&P 500 shed 0.68% on the day, with high-valuation growth stocks taking the biggest hit.

Index Rebalancing and Rotation

ALAB was added to the Nasdaq-100 effective June 22. Passive fund buying ahead of the inclusion helped push the stock higher in recent weeks. That tailwind has now reversed, with index rebalancing contributing to selling pressure.

Investors are also rotating out of high-momentum names and into defensive sectors like health care and utilities.

Technically, the stock has pulled 12.8% below its 20-day moving average. Its RSI sits at 46, off overbought levels from June but not yet oversold. Support is seen around $303, with resistance near $372.

Fundamentals Remain Strong

Despite the drop, the underlying business has been performing well. In its most recent quarter, ALAB reported EPS of $0.61, beating estimates by $0.07. Revenue came in at $308 million, up 93.5% year over year and ahead of the $292 million consensus.

The company guided Q2 2026 EPS at $0.68 to $0.70. Analysts on average expect full-year EPS of $1.88.

The stock still trades at a lofty PE of 251 and a market cap of $63.77 billion. With 12 analysts rating it Buy and 11 Hold, the consensus sits at Moderate Buy with an average price target of $265.75 — well below current levels even after Monday’s drop.

ALAB was down 13.45% at $399 at the time of publication.